About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Viewers tuning in to College Football Playoff games earlier this month were given an early introduction to the newest group of future consumers. Generation Beta, beginning to be born in 2025, had a ...
Alpha release is the initial software version for limited testing, while Beta is for broader testing and feedback before the final release. An alpha release is an under-development version of software ...
Whether you inherit alpha- or beta-thalassemia depends on which genes are affected. The number of affected genes can determine the subtype of alpha- or beta-thalassemia and the severity of your ...
Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition. On Monday, the FDA gave ...
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback